---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-303831"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:34:39.071102+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mirum receives EC approval for LIVMARLI in Alagille syndrome across EU

## Summary
- European Commission granted marketing authorization for LIVMARLI (maralixibat) oral solution.
- Indicated for cholestatic pruritus in Alagille syndrome patients aged 2 months and older.
- First and only approved treatment for ALGS in both EU and US; ALGS affects 1 in 30,000 globally.
- Approval follows positive CHMP opinion from September 2022.
- Authorization covers all 27 EU member states for marketing.

## SEC filing metadata
- accession: 0001193125-22-303831
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312522303831/0001193125-22-303831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312522303831/d384957d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-303831
- JSON: https://secwatch.observer/filing/0001193125-22-303831.json
- Plain text: https://secwatch.observer/filing/0001193125-22-303831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.